RxDoctor Payments Data

Herbert Tiquia, MD

Nephrology · Garden Grove, CANPI 1902875693

Payments from drug & device makers

$2,919in general payments, 2019–2025

Across 100 payments — averaging $29.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$709
  • AstraZeneca$476
  • Novartis$392
  • Travere Therapeutics, Inc.$217
  • Akebia Therapeutics Inc$209
  • Baxter Healthcare$131
  • plus $785 from 10 others

What the payments were for

  • Food & beverage$2,81096%
  • Education$1094%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,919 in reported general payments places this provider in the 60th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$304,090
Medicare patients
536
Services billed
2,710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol38$37,669
Sevelamer Carbonate60$18,627
AuryxiaFerric Citrate11$11,970
RetacritEpoetin Alfa-Epbx52$11,516
TradjentaLinagliptin17$9,389
Tacrolimus17$5,651
ProcritEpoetin Alfa11$4,651
Calcium Acetate66$3,974
Febuxostat24$2,081
Potassium Citrate ErPotassium Citrate12$1,619
Cinacalcet Hcl22$1,225
Allopurinol95$1,008
Losartan Potassium87$919
Bumetanide28$682
Amlodipine Besylate97$619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$476$37,66938 claims
Akebia Therapeutics IncAuryxia$209$11,97011 claims
Boehringer IngelheimTradjenta$17$9,38917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,341 nephrology providers in California.

Other nephrology in Garden Grove

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →